Skip to content

Clinical trials

Diabetes, Gestational trials in Canada

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Diabetes, Gestational Country / region: Canada Clear all

46 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20011
20021
20031
20041
20061
20081
20093
20104
20113
20123
20131
20146
20152
20162
20171
20181
20192
20202
20222
20232
20242
20252
20262

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed22
Active, not recruiting7
Unknown status7
Recruiting5
Terminated3
Not yet recruiting2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Université de Sherbrooke9
University of Manitoba5
McGill University Health Centre/Research Institute of the McGill University Health Centre4
Laval University3
Mount Sinai Hospital, Canada3
University of Toronto3
Ottawa Hospital Research Institute2
Queen's University2
Samuel Lunenfeld Research Institute, Mount Sinai Hospital2
Anthony Hanley1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Diabetes, Gestational46
Diabetes Mellitus, Type 211
Insulin Resistance4
Obesity3
Diabetes Mellitus2
Hyperglycemia2
Pregnancy Complications2
Breast Neoplasms1
Cardiovascular Diseases1
Disease1

Trials

Showing 76 to 46 of 46. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.